Madelynn Whittaker
boston-based scientist editing DNA and occasionally her coffee order
- Reposted by Madelynn Whittaker[Not loaded yet]
- Reposted by Madelynn WhittakerPersonalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The @fda.gov outlines a path to market entry for products where a randomized trial is not feasible. Learn more: nej.md/4nUQdcl
- Reposted by Madelynn Whittaker[Not loaded yet]
- My first-author paper was published today in Nature Biomedical Engineering! Here we describe how incorporating DNA substitutions into various positions of the Cas9 guide RNA protospacer can enhance the precision and performance of adenine base editors. 🧬 ✂️
